Review



tti 101  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress tti 101
    A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated <t>with</t> <t>TTI-101</t> (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).
    Tti 101, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 37 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tti 101/product/MedChemExpress
    Average 94 stars, based on 37 article reviews
    tti 101 - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3"

    Article Title: BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3

    Journal: Cell Death & Disease

    doi: 10.1038/s41419-025-08294-5

    A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated with TTI-101 (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).
    Figure Legend Snippet: A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated with TTI-101 (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).

    Techniques Used:

    IHC of BRUCE, PTEN and pSTAT3-Y705 in consecutive liver sections from healthy individuals and MASH specimens at 40x ( A , scale bar 400 µm) and 200x magnification ( B , scale bar 100 µm) shows nuclear pSTAT3-Y705 positivity only in MASH livers, with quantification shown ( C ). Birc6 ( D ) and Pten ( E ) expression across normal livers and MASH fibrosis stages F0-F4 were analyzed using GEO2R, with Birc6 and Pten co-expression ( F ) and Stat3 expression ( G ) shown. Birc6 ( H ) and Pten ( I ) expression in normal and MASH livers with varying NAS scores were also analyzed. All data were from the GSE162694 dataset. ( J ) A model illustrating BRUCE/PTEN-STAT3 axis in MASLD/MASH regulation: The combined loss of BRUCE (BRUCE→mt→FAO) and PTEN (PTEN┫AKT → DNL) creates a ‘double hit’ that exacerbates MASLD. BRUCE deficiency impairs mitochondrial metabolism (specifically, fatty acid oxidation, respiration, and bioenergetics), while PTEN loss activates the AKT pathway, promoting de novo lipogenesis. Together, these defects intensify hepatic lipid accumulation, driving MASLD. Additionally, BRUCE loss increases DNA damage, apoptosis, and compensatory hepatocyte proliferation, further elevating oxidative stress. This cumulative oxidative stress, amplified by AKT-driven oxidative stress signals, triggers STAT3 activation in both hepatocytes and non-parenchymal cells, driving progression to MASH with fibrosis, which can be mitigated by STAT3 inhibitor TTI-101. Yellow-highlighted areas represent steatosis-promoting events. mt: mitochondria. *** p < 0.001 by student’s t test. Normal ( n = 5), MASH ( n = 4), with representative images quantified ( n = 8). Normal histology ( n = 33), F0 ( n = 33), F1 ( n = 30), F2 ( n = 27), F3 ( n = 8), F4 ( n = 12).
    Figure Legend Snippet: IHC of BRUCE, PTEN and pSTAT3-Y705 in consecutive liver sections from healthy individuals and MASH specimens at 40x ( A , scale bar 400 µm) and 200x magnification ( B , scale bar 100 µm) shows nuclear pSTAT3-Y705 positivity only in MASH livers, with quantification shown ( C ). Birc6 ( D ) and Pten ( E ) expression across normal livers and MASH fibrosis stages F0-F4 were analyzed using GEO2R, with Birc6 and Pten co-expression ( F ) and Stat3 expression ( G ) shown. Birc6 ( H ) and Pten ( I ) expression in normal and MASH livers with varying NAS scores were also analyzed. All data were from the GSE162694 dataset. ( J ) A model illustrating BRUCE/PTEN-STAT3 axis in MASLD/MASH regulation: The combined loss of BRUCE (BRUCE→mt→FAO) and PTEN (PTEN┫AKT → DNL) creates a ‘double hit’ that exacerbates MASLD. BRUCE deficiency impairs mitochondrial metabolism (specifically, fatty acid oxidation, respiration, and bioenergetics), while PTEN loss activates the AKT pathway, promoting de novo lipogenesis. Together, these defects intensify hepatic lipid accumulation, driving MASLD. Additionally, BRUCE loss increases DNA damage, apoptosis, and compensatory hepatocyte proliferation, further elevating oxidative stress. This cumulative oxidative stress, amplified by AKT-driven oxidative stress signals, triggers STAT3 activation in both hepatocytes and non-parenchymal cells, driving progression to MASH with fibrosis, which can be mitigated by STAT3 inhibitor TTI-101. Yellow-highlighted areas represent steatosis-promoting events. mt: mitochondria. *** p < 0.001 by student’s t test. Normal ( n = 5), MASH ( n = 4), with representative images quantified ( n = 8). Normal histology ( n = 33), F0 ( n = 33), F1 ( n = 30), F2 ( n = 27), F3 ( n = 8), F4 ( n = 12).

    Techniques Used: Expressing, Amplification, Activation Assay



    Similar Products

    94
    MedChemExpress tti 101
    A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated <t>with</t> <t>TTI-101</t> (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).
    Tti 101, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tti 101/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    tti 101 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress intraperitoneal injection
    A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated <t>with</t> <t>TTI-101</t> (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).
    Intraperitoneal Injection, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/intraperitoneal injection/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    intraperitoneal injection - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress c188 9
    A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated <t>with</t> <t>TTI-101</t> (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).
    C188 9, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c188 9/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    c188 9 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    Selleck Chemicals stat3 inhibitor c188-9 s8605
    A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated <t>with</t> <t>TTI-101</t> (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).
    Stat3 Inhibitor C188 9 S8605, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/stat3 inhibitor c188-9 s8605/product/Selleck Chemicals
    Average 90 stars, based on 1 article reviews
    stat3 inhibitor c188-9 s8605 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated with TTI-101 (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).

    Journal: Cell Death & Disease

    Article Title: BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3

    doi: 10.1038/s41419-025-08294-5

    Figure Lengend Snippet: A WB of liver lysates from 2-month-old mice (upper) and IHC of pSTAT3-Y705 with WT and DKO liver sections showing nuclear positivity of pSTAT3-Y705 both in hepatocytes and NPCs in DKO (lower); scale bar 50 µm. B Liver images of WT and DKO mice treated with TTI-101 (100 mg/kg/bw, daily i.p.) for 3 weeks or left untreated with liver-to-body weight ratio quantified; scale bar 1 cm. These mice were analyzed by WB for indicated proteins ( C ), ORO ( D ), H&E ( E ), Sirius Red ( F ) and IHC for α-SMA, scale bar 50 µm ( G ) with quantification below. n.s.: not significant, ** p < 0.01, *** p < 0.001 by 2-way ANOVA. Mice per genotype ( n = 3) with representative images quantified ( n = 4–11).

    Article Snippet: For STAT3 inhibition, 2-month-old WT and DKO mice received daily intraperitoneal injection of TTI-101 (MedChemExpress HY-112288; 100 mg/kg) for three weeks.

    Techniques:

    IHC of BRUCE, PTEN and pSTAT3-Y705 in consecutive liver sections from healthy individuals and MASH specimens at 40x ( A , scale bar 400 µm) and 200x magnification ( B , scale bar 100 µm) shows nuclear pSTAT3-Y705 positivity only in MASH livers, with quantification shown ( C ). Birc6 ( D ) and Pten ( E ) expression across normal livers and MASH fibrosis stages F0-F4 were analyzed using GEO2R, with Birc6 and Pten co-expression ( F ) and Stat3 expression ( G ) shown. Birc6 ( H ) and Pten ( I ) expression in normal and MASH livers with varying NAS scores were also analyzed. All data were from the GSE162694 dataset. ( J ) A model illustrating BRUCE/PTEN-STAT3 axis in MASLD/MASH regulation: The combined loss of BRUCE (BRUCE→mt→FAO) and PTEN (PTEN┫AKT → DNL) creates a ‘double hit’ that exacerbates MASLD. BRUCE deficiency impairs mitochondrial metabolism (specifically, fatty acid oxidation, respiration, and bioenergetics), while PTEN loss activates the AKT pathway, promoting de novo lipogenesis. Together, these defects intensify hepatic lipid accumulation, driving MASLD. Additionally, BRUCE loss increases DNA damage, apoptosis, and compensatory hepatocyte proliferation, further elevating oxidative stress. This cumulative oxidative stress, amplified by AKT-driven oxidative stress signals, triggers STAT3 activation in both hepatocytes and non-parenchymal cells, driving progression to MASH with fibrosis, which can be mitigated by STAT3 inhibitor TTI-101. Yellow-highlighted areas represent steatosis-promoting events. mt: mitochondria. *** p < 0.001 by student’s t test. Normal ( n = 5), MASH ( n = 4), with representative images quantified ( n = 8). Normal histology ( n = 33), F0 ( n = 33), F1 ( n = 30), F2 ( n = 27), F3 ( n = 8), F4 ( n = 12).

    Journal: Cell Death & Disease

    Article Title: BRUCE liver-KO enhances MASLD/MASH development in the steatotic PTEN-KO background by impairing mitochondrial metabolism and activating STAT3

    doi: 10.1038/s41419-025-08294-5

    Figure Lengend Snippet: IHC of BRUCE, PTEN and pSTAT3-Y705 in consecutive liver sections from healthy individuals and MASH specimens at 40x ( A , scale bar 400 µm) and 200x magnification ( B , scale bar 100 µm) shows nuclear pSTAT3-Y705 positivity only in MASH livers, with quantification shown ( C ). Birc6 ( D ) and Pten ( E ) expression across normal livers and MASH fibrosis stages F0-F4 were analyzed using GEO2R, with Birc6 and Pten co-expression ( F ) and Stat3 expression ( G ) shown. Birc6 ( H ) and Pten ( I ) expression in normal and MASH livers with varying NAS scores were also analyzed. All data were from the GSE162694 dataset. ( J ) A model illustrating BRUCE/PTEN-STAT3 axis in MASLD/MASH regulation: The combined loss of BRUCE (BRUCE→mt→FAO) and PTEN (PTEN┫AKT → DNL) creates a ‘double hit’ that exacerbates MASLD. BRUCE deficiency impairs mitochondrial metabolism (specifically, fatty acid oxidation, respiration, and bioenergetics), while PTEN loss activates the AKT pathway, promoting de novo lipogenesis. Together, these defects intensify hepatic lipid accumulation, driving MASLD. Additionally, BRUCE loss increases DNA damage, apoptosis, and compensatory hepatocyte proliferation, further elevating oxidative stress. This cumulative oxidative stress, amplified by AKT-driven oxidative stress signals, triggers STAT3 activation in both hepatocytes and non-parenchymal cells, driving progression to MASH with fibrosis, which can be mitigated by STAT3 inhibitor TTI-101. Yellow-highlighted areas represent steatosis-promoting events. mt: mitochondria. *** p < 0.001 by student’s t test. Normal ( n = 5), MASH ( n = 4), with representative images quantified ( n = 8). Normal histology ( n = 33), F0 ( n = 33), F1 ( n = 30), F2 ( n = 27), F3 ( n = 8), F4 ( n = 12).

    Article Snippet: For STAT3 inhibition, 2-month-old WT and DKO mice received daily intraperitoneal injection of TTI-101 (MedChemExpress HY-112288; 100 mg/kg) for three weeks.

    Techniques: Expressing, Amplification, Activation Assay